

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

---

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): **May 2, 2017**

**IDEXX LABORATORIES, INC.**

*(Exact name of registrant as specified in its charter)*

**Delaware**  
*(State or other jurisdiction  
of incorporation)*

**000-19271**  
*(Commission File Number)*

**01-0393723**  
*(IRS Employer Identification No.)*

**One IDEXX Drive, Westbrook, Maine**  
*(Address of principal executive offices)*

**04092**  
*(ZIP Code)*

**207.556.0300**  
*(Registrant's telephone number, including area code)*

**Not Applicable**  
*(Former name or former address, if changed since last report)*

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

On May 3, 2017, IDEXX Laboratories, Inc. (the "Company") held its 2017 annual meeting of stockholders (the "Annual Meeting"), at which a quorum was present in person or by proxy.

At the Annual Meeting, stockholders considered and voted on the following proposals, each of which is described in more detail in the Company's proxy statement dated March 23, 2017, (the "Proxy Statement"): (1) the election of three Class II directors for terms expiring at the 2020 annual meeting of stockholders; (2) the ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered accounting firm for the current fiscal year; (3) the approval, on an advisory basis, of the compensation of the Company's named executive officers; and (4) an advisory vote on how frequently we should seek an advisory vote on the compensation of our named executive officers as presented in the Company's proxy statement delivered to stockholders in connection with the Annual Meeting.

The voting results at the Annual Meeting with respect to each of the matters described above, were as follows:

Proposal One: Election of Directors

<b>Nominees</b>	<b>For</b>	<b>Against</b>	<b>Abstain</b>	<b>Broker Non-Votes</b>
Rebecca M. Henderson, PhD	69,701,078	1,440,416	31,660	8,978,293
Lawrence D. Kingsley	70,831,533	304,217	37,404	8,978,293
Sophie V. Vandebroek, PhD	67,914,847	3,230,036	28,271	8,978,293

Proposal Two: Ratification of Appointment of Independent Registered Public Accounting Firm

<b>For</b>	79,240,456
<b>Against</b>	879,502
<b>Abstain</b>	31,489
<b>Broker Non-Votes</b>	N/A

Proposal Three: Advisory Vote to Approve Executive Compensation

<b>For</b>	64,921,042
<b>Against</b>	6,160,819
<b>Abstain</b>	91,293
<b>Broker Non-Votes</b>	8,978,293

Proposal Four: Advisory Vote on Frequency of Approval of Executive Compensation

<b>One Year</b>	65,065,303
<b>Two Years</b>	84,157
<b>Three Years</b>	5,942,572
<b>Abstain</b>	81,122
<b>Broker Non-Votes</b>	8,978,293

**Item 8.01 Other Events.**

On May 2, 2017, the Company's Board of Directors authorized an increase in the Company's ongoing share repurchase program, authorizing the repurchase of up to three million additional shares of the Company's Common Stock for a total of sixty-eight million shares as of May 2, 2017. Repurchases may be made in the open market (including through Rule 10b5-1 plans) or in negotiated transactions. These shares are in addition to the 3,297,887 shares remaining under the Company's ongoing share repurchase program as of April 28, 2017, pursuant to previous Board authorization. The timing and amount of any repurchases will be at the discretion of the Company's management. The increase in the number of shares authorized under the share repurchase plan is described in a press release issued by the Company on May 3, 2017, which is attached hereto as Exhibit 99.1.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

The following exhibit is furnished as part of this Report pursuant to Item 8.01.

- 99.1 Press Release entitled "IDEXX Laboratories Announces Increase in Share Repurchase Program" issued by the Company on May 3, 2017.
-

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**IDEXX LABORATORIES, INC.**

Date: May 5, 2017

By: /s/ Jacqueline L. Studer  
Jacqueline L. Studer  
Corporate Vice President, General Counsel and  
Secretary

---

**EXHIBIT INDEX**

<u>Exhibit No.</u>	<u>Description of Exhibit</u>
99.1	Press Release entitled "IDEXX Laboratories Announces Increase in Share Repurchase Program" issued by the Company on May 3, 2017.

---



FOR IMMEDIATE RELEASE

## IDEXX Laboratories Announces Increase in Share Repurchase Program

**WESTBROOK, Maine, May 3, 2017** — IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in veterinary diagnostics, veterinary practice software and water microbiology testing, today announced that the repurchase by the Company of up to an additional 3.0 million shares of its common stock under its ongoing share repurchase program has been authorized. Repurchases may be made in the open market (including through Rule 10b5-1 plans) or in negotiated transactions. These shares are in addition to the 3,297,887 shares remaining under the Company's share repurchase program as of April 28, 2017, pursuant to previous Board authorizations. The timing and amount of any repurchases will be at the discretion of the Company's management.

### **About IDEXX Laboratories, Inc.**

IDEXX Laboratories, Inc. is a member of the S&P 500® Index and is a leader in pet healthcare innovation, serving practicing veterinarians around the world with a broad range of diagnostic and information technology-based products and services. IDEXX products enhance the ability of veterinarians to provide advanced medical care, improve staff efficiency and build more economically successful practices. IDEXX is also a worldwide leader in providing diagnostic tests and information for livestock and poultry and tests for the quality and safety of water and milk. Headquartered in Maine, IDEXX Laboratories employs more than 7,000 people and offers products to customers in over 175 countries. For more information about IDEXX, visit: [www.idexx.com](http://www.idexx.com).

*Contact:*

### ***Investor Relations:***

*Kerry Bennett  
207-556-8155*

---